

# Nimer S Alkhatib

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/34425/publications.pdf>

Version: 2024-02-01

26  
papers

172  
citations

1307594

7  
h-index

1199594

12  
g-index

27  
all docs

27  
docs citations

27  
times ranked

237  
citing authors

#	ARTICLE	IF	CITATIONS
1	Economic analysis of glucagon like peptide-1 receptor agonists from the Saudi Arabia payer perspective. Saudi Pharmaceutical Journal, 2022, 30, 433-439.	2.7	3
2	Cost-effectiveness of palonosetron and dexamethasone-based triple and quadruple regimens in preventing highly emetogenic chemotherapy-induced nausea and vomiting. Current Medical Research and Opinion, 2022, , 1-7.	1.9	2
3	Validation of the Arabic version of medication adherence report scale questionnaire and beliefs about medication -specific questionnaire: A factor analysis study. PLoS ONE, 2022, 17, e0266606.	2.5	3
4	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	2.2	3
5	Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients. Current Medical Research and Opinion, 2021, 37, 1-8.	1.9	0
6	Gender-stratified hierarchical modeling of patient and physician determinants of antihypertensive treatment outcomes: pooled analysis of seven prospective real-world studies with 17,044 patients. Current Medical Research and Opinion, 2021, 37, 367-375.	1.9	2
7	What Are the Factors Associated with Nonadherence to Medications in Patients with Chronic Diseases?. Healthcare (Switzerland), 2021, 9, 1237.	2.0	10
8	Pricing methods in outcome-based contracting: $\hat{\Gamma}4$ : safety-based pricing. Journal of Medical Economics, 2020, 23, 1237-1245.	2.1	4
9	Pricing methods in outcome-based contracting: $\hat{\Gamma}5$ : risk of efficacy failure-based pricing. Journal of Medical Economics, 2020, 23, 1246-1255.	2.1	4
10	Pricing methods in outcome-based contracting: $\hat{\Gamma}1$ : cost effectiveness analysis and cost-utility analysis-based pricing. Journal of Medical Economics, 2020, 23, 1215-1222.	2.1	8
11	Pricing methods in outcome-based contracting: $\hat{\Gamma}2$ : willingness-to-pay-based pricing. Journal of Medical Economics, 2020, 23, 1223-1229.	2.1	7
12	Pricing methods in outcome-based contracting: $\hat{\Gamma}6$ : adherence-based pricing. Journal of Medical Economics, 2020, 23, 1256-1265.	2.1	4
13	Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 $\hat{\Gamma}$ 's). Journal of Medical Economics, 2020, 23, 1266-1272.	2.1	6
14	Pricing methods in outcome-based contracting: $\hat{\Gamma}3$ : reference-based pricing. Journal of Medical Economics, 2020, 23, 1230-1236.	2.1	9
15	Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective. Critical Care Medicine, 2020, 48, e906-e911.	0.9	2
16	Insulin injection technique in Western region of Algeria, Tlemcen. Pan African Medical Journal, 2020, 36, 327.	0.8	2
17	Comparative efficacy and safety of immunotherapies targeting the PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: A Bayesian network meta-analysis. Critical Reviews in Oncology/Hematology, 2019, 142, 16-25.	4.4	28
18	The Importance of Outcome and Precise Evaluation in Economic Analysis of Cancer Drugsâ€”Reply. JAMA Dermatology, 2019, 155, 863.	4.1	0

#	ARTICLE	IF	CITATIONS
19	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. <i>Leukemia Research</i> , 2019, 85, 106215.	0.8	8
20	Network meta-analysis of nine large cardiovascular outcome trials of new antidiabetic drugs. <i>Primary Care Diabetes</i> , 2019, 13, 204-211.	1.8	16
21	Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. <i>JAMA Dermatology</i> , 2019, 155, 22.	4.1	25
22	Economic evaluation crizotinib, alectinib and brigatinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20714-e20714.	1.6	1
23	Economic evaluation of anaplastic lymphoma kinase (ALK) inhibitors brigatinib, alectinib and crizotinib in non-small cell lung cancer (NSCLC): Analysis for intracranial metastasis-related progression free survival (CNSPFS).. <i>Journal of Clinical Oncology</i> , 2019, 37, e20515-e20515.	1.6	0
24	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018, 3, 319-329.	0.7	3
25	Economic evaluation of a pharmacogenomic multi-gene panel test to optimize anti-hypertension therapy: simulation study. <i>Journal of Medical Economics</i> , 2018, 21, 1246-1253.	2.1	6
26	Economic Evaluation for the US of Ibrutinib Versus Acalabrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma. <i>Blood</i> , 2018, 132, 4829-4829.	1.4	1